Detalles de la búsqueda
1.
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
J Antimicrob Chemother
; 78(1): 272-275, 2022 12 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411257
2.
Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study.
HIV Med
; 23(6): 629-638, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34951111
3.
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.
J Antimicrob Chemother
; 76(5): 1277-1285, 2021 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33501504
4.
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
BMC Infect Dis
; 19(1): 246, 2019 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30871487
5.
HLA A*32 is associated to HIV acquisition while B*44 and B*53 are associated with protection against HIV acquisition in perinatally exposed infants.
BMC Pediatr
; 19(1): 249, 2019 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31337377
6.
Maternal age, infant age, feeding options, single/multiple pregnancy, type of twin sets and mother-to-child transmission of HIV.
J Trop Pediatr
; 65(3): 280-286, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30125009
7.
Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens.
Viruses
; 15(8)2023 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37632026
8.
HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon.
Medicine (Baltimore)
; 102(22): e33897, 2023 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37266631
9.
Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens.
Viruses
; 15(7)2023 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37515146
10.
Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era.
J Public Health Afr
; 14(10): 2612, 2023 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38020274
11.
HIV-1 subtype diversity and immuno-virological outcomes among adolescents failing antiretroviral therapy in Cameroon: A cohort study.
PLoS One
; 18(10): e0293326, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878637
12.
HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis.
PLOS Glob Public Health
; 2(10): e0000826, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36962573
13.
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
Sci Rep
; 12(1): 1374, 2022 01 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35082353
14.
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.
Diagn Microbiol Infect Dis
; 102(2): 115574, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34864527
15.
Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings.
Microbiol Spectr
; 10(6): e0342022, 2022 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36259973
16.
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Viruses
; 15(1)2022 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36680058
17.
HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol.
PLoS One
; 16(7): e0253587, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34197501
18.
HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol.
Syst Rev
; 9(1): 93, 2020 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32334643
19.
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Antimicrob Resist Infect Control
; 9(1): 143, 2020 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32843050
20.
TRIM5α 136Q, CCR5 Promoter 59029G And CCR264I Alleles Impact The Progression Of HIV In Children And Adolescents.
Appl Clin Genet
; 12: 203-211, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31807050